Literature DB >> 15749038

Aminoterminal propeptide of type III procollagen and matrix metalloproteinases-2 and -9 failed to serve as serum markers for abdominal aortic aneurysm.

T Eugster1, A Huber, T Obeid, I Schwegler, L Gürke, P Stierli.   

Abstract

OBJECTIVES: Matrix-metalloproteinase (MMP)-2 and -9 and aminoterminal propeptide of type III collagen (NIIINP) have been reported to be elevated in patients with abdominal aortic aneurysm (AAA). The aim of our study was to test NIIINP, MMP-2 and -9 as potential serum markers for AAA in a large population group at risk for AAA.
METHODS: Fifty-five to 70 year old men were screened for AAA by abdominal ultrasound. Simultaneously, blood samples were taken and the patients were interviewed for known risk factors for AAA. Patients with a dilatation of the infrarenal aorta of > or =25mm (Group 1, n=76) were compared to randomly assigned patients with normal aortic diameters (Group 2, n=83). A third group consisted of patients scheduled for operation of AAA (n=19).
RESULTS: A total of 987 men were investigated with ultrasound. Seventy-six (7.7%) had an aortic dilatation > or =25mm. Aortic dilatation was correlated with age (P=0.0001). However, serum levels of NIIINP and MMP 2 were not different between the three groups of patients. For MMP-9 there was a weak inverse correlation with lower serum levels in patients with aortic dilatation (P=0.043).
CONCLUSIONS: Both MMP-2 and -9 and NIIINP failed to show relevance as serum markers for aortic dilatation. Our results are, therefore, in contradiction to previous published results. AAAs cannot be diagnosed with a simple blood test.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749038     DOI: 10.1016/j.ejvs.2004.12.007

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  13 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 3.  Biomarkers of AAA progression. Part 1: extracellular matrix degeneration.

Authors:  Femke A M V I Hellenthal; Willem A Buurman; Will K W H Wodzig; Geert Willem H Schurink
Journal:  Nat Rev Cardiol       Date:  2009-05-26       Impact factor: 32.419

4.  Differential effect of 17-beta-estradiol on smooth muscle cell and aortic explant MMP2.

Authors:  Derek T Woodrum; John W Ford; Brenda S Cho; Kevin K Hannawa; James C Stanley; Peter K Henke; Gilbert R Upchurch
Journal:  J Surg Res       Date:  2008-08-15       Impact factor: 2.192

5.  Circulating tetrahydrobiopterin as a novel biomarker for abdominal aortic aneurysm.

Authors:  Kin Lung Siu; Hua Cai
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-26       Impact factor: 4.733

Review 6.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 7.  Diagnosis and monitoring of abdominal aortic aneurysm: current status and future prospects.

Authors:  Joseph V Moxon; Adam Parr; Theophilus I Emeto; Philip Walker; Paul E Norman; Jonathan Golledge
Journal:  Curr Probl Cardiol       Date:  2010-10       Impact factor: 5.200

Review 8.  Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms.

Authors:  Yanwen Qin; Xu Cao; Yaoguo Yang; Guo-Ping Shi
Journal:  Future Cardiol       Date:  2013-01

Review 9.  Circulating markers of abdominal aortic aneurysm presence and progression.

Authors:  Jonathan Golledge; Philip S Tsao; Ronald L Dalman; Paul E Norman
Journal:  Circulation       Date:  2008-12-02       Impact factor: 29.690

Review 10.  Abdominal Aortic Aneurysm: Evolving Controversies and Uncertainties.

Authors:  Davide Carino; Timur P Sarac; Bulat A Ziganshin; John A Elefteriades
Journal:  Int J Angiol       Date:  2018-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.